RxDoctor Payments Data

Rachel Richardson, DO

Internal Medicine · Southaven, MSNPI 1235457789

Payments from drug & device makers

$3,112in general payments, 2019–2025

Across 223 payments — averaging $13.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$647
  • AbbVie$446
  • Lilly USA, LLC$418
  • Amarin Pharma, Inc.$226
  • Takeda Pharmaceuticals U.S.A., Inc.$172
  • Pfizer$163
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$3,112100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,112 in reported general payments places this provider in the 80th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$148,626
Medicare patients
484
Services billed
3,715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin62$79,221
OzempicSemaglutide49$72,028
MounjaroTirzepatide48$66,339
FarxigaDapagliflozin Propanediol22$27,720
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$20,520
EliquisApixaban15$19,050
VascepaIcosapent Ethyl25$18,189
RybelsusSemaglutide15$16,812
JanuviaSitagliptin Phosphate13$15,438
LinzessLinaclotide13$14,086
Rosuvastatin Calcium266$2,429
Atorvastatin Calcium232$1,808
Levothyroxine Sodium140$1,720
Amlodipine Besylate247$1,519
Gabapentin78$1,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$647$88,84064 claims
Boehringer IngelheimJardiance$121$79,22162 claims
Lilly USA, LLCMounjaro$418$66,33948 claims
AstraZenecaFarxiga$133$27,72022 claims
GSKTrelegy Ellipta$79$20,52011 claims
PfizerEliquis$163$19,05015 claims
MerckJanuvia$42$15,43813 claims
AbbVieLinzess, Synthroid$446$15,32431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Southaven

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →